Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Clinical trial NCT00529035 · COMPLETED
Trial details
- NCT number
- NCT00529035
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-08-01
- Primary completion
- 2011-06-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.